Vascular endothelial growth factor induces manganese-superoxide dismutase expression in endothelial cells by a Rac1-regulated NADPH oxidase-dependent mechanism.

Vascular endothelial growth factor (VEGF) is a potent vascular endothelial cell-specific mitogen that modulates endothelial cell function. In the present study, we show that VEGF induces manganese-superoxide dismutase (MnSOD) mRNA and protein in human coronary artery endothelial cells (HCAEC) and pulmonary artery endothelial cells. VEGF-mediated induction of MnSOD mRNA was inhibited by pretreatment with the NADPH oxidase inhibitors, diphenyleneiodonium (DPI), and 4-(2-aminoethyl)-benzenesulfonyl fluoride, but not with the nitric oxide synthase inhibitor L-NAME (N-monomethyl-L-arginine) or the xanthine oxidase inhibitor allopurinol. VEGF stimulation of MnSOD was also inhibited by adenoviral-mediated overexpression of catalase Cu, Zn-SOD and a dominant-negative form of the small GTPase component of NADPH oxidase Rac1 (Rac1N17). Treatment of HCAEC with VEGF resulted in a transient increase in ROS production at 20 min, as measured by 2,7-dichlorodihydrofluorescein oxidation. This effect was abrogated by expression of Rac1N17. Taken together, these findings suggest that VEGF induces MnSOD by an NADPH oxidase-dependent mechanism and that VEGF signaling in the endothelium is coupled to the redox state of the cell.

Epidermal growth factor induces Egr-1 promoter activity in hepatocytes in vitro and in vivo.

Early growth response-1 (Egr-1) is a transcription factor that couples short-term changes in the extracellular milieu to long-term changes in gene expression. Under in vitro conditions, the Egr-1 gene has been shown to respond to many extracellular signals. In most cases, these findings have not been extended to the in vivo setting. The goal of the present study was to explore the role of epidermal growth factor (EGF) in mediating Egr-1 expression in hepatocytes under both in vitro and in vivo conditions. In HepG2 cells, Egr-1 protein and mRNA were upregulated in the presence of EGF. In stable transfections of HepG2 cells, a 1,200-bp Egr-1 promoter contained information for EGF response via a protein kinase C-independent, mitogen-activated protein kinase-dependent signaling pathway. A promoter region containing the two most proximal serum response elements was sufficient to transduce the EGF signal. In transgenic mice that carry the Egr-1 promoter coupled to the LacZ reporter gene, systemic delivery of EGF by intraperitoneal injection resulted in an induction of the endogenous Egr-1 gene and the Egr-1-lacZ transgene in hepatocytes. Together, these results suggest that the 1,200-bp promoter contains information for EGF response in hepatocytes both in vitro and in intact animals.

NADPH oxidase activity is required for endothelial cell proliferation and migration.

NADPH oxidase has been shown to play an important role in cardiovascular biology. The goal of the present study was to determine whether NADPH oxidase activity is important for endothelial cell growth and migration. In proliferation assays, growth factor- or serum-induced DNA synthesis in three different types of human endothelial cells was abrogated by inhibitors of NADPH oxidase, but not by inhibitors of xanthine oxidase or nitric oxide synthase. Moreover, vascular endothelial growth factor-induced migration of human endothelial cells was suppressed in the presence of NADPH oxidase inhibitors. These results support a potential role for NADPH oxidase in mediating angiogenesis.

An 11-amino acid sequence from c-met initiates epithelial chemotaxis via phosphatidylinositol 3-kinase and phospholipase C.

Interaction of hepatocyte growth factor with its high affinity receptor c-met initiates a cascade of intracellular events leading to epithelial motility. An 11-amino acid sequence from the c-met receptor has been found to cause cell transformation in transfected fibroblasts (Ponzetto, C., Bardelli, A., Zhen, Z., Maina, F., Dalla, Z. P., Giordano, S., Graziani, A., Panayotou, G., and Comoglio, P. M.(1994) Cell 77, 261-271). We inserted this sequence into a mutant platelet-derived growth factor receptor (F5) to determine if this region of c-met can initiate cell motility and which signaling pathways it activates. The platelet-derived growth factor (PDGF) receptor/c-met hybrid (F5 met) initiated PDGF-dependent chemotaxis in renal epithelial cells (8.0 +/- 2.3 versus 70.5 +/- 4.8 cells/mm2), while the parental construct, F5, did not. Addition of PDGF to cells expressing F5 met caused activation of the phosphatidylinositol (PI) 3-kinase (control 2.0 +/- 0.8, +PDGF 17.1 +/- 5.1, n = 3, p < 0.05) and phospholipase C (control 478.5 +/- 67 dpm/well, +PDGF 1049.3 +/- 93, n = 4, p = 0.003), while neither pathway was activated in cells expressing F5. The chemotactic response of F5 met was inhibited by both the PI 3-kinase inhibitor wortmannin and the phospholipase C inhibitor U-71322. Selective activation of the PI 3-kinase utilizing a PDGF receptor mutant (F3) containing the native high affinity PI 3-kinase binding site also resulted in PDGF stimulated chemotaxis, although less than that generated by the c-met sequence. These findings demonstrate that the 11-amino acid sequence from c-met initiates epithelial motility via coincident activation of the PI 3-kinase and phospholipase C and that selective activation of the PI 3-kinase can initiate a partial chemotactic response.

Effect of myo-inositol on renal Na-K-ATPase in experimental diabetes.

The activity of Na-K-ATPase in the kidney is increased by experimental diabetes. Because the kidney is rich in myo-inositol and abnormal inositol metabolism has been implicated in early neural complications of diabetes, we studied the effect of myo-inositol supplementation on Na-K-ATPase activity in renal medullary and cortical homogenates of Sprague-Dawley rats made diabetic with streptozotocin. Myo-inositol (650 mg/kg) was administered by gavage daily for 1 and 2 weeks after induction of diabetes. Medullary Na-K-ATPase (mumol/mg protein/h) was increased at 1 week by approximately 60% in diabetic rats versus control (25.9 +/- 0.07 vs 16.3 +/- 0.7; P less than .01). This increase was completely prevented by myo-inositol supplementation, despite persistent hyperglycemia. At 2 weeks, similar results were seen; medullary Na-K-ATPase activity was increased by 50% in diabetic rats compared with control, and once again myo-inositol prevented this increase. Sorbinil, the aldose reductase inhibitor, was also administered by gavage (20 mg/kg) for 2 weeks and partially prevented the increase in medullary Na-K-ATPase activity (20.0 +/- 0.9; P less than .05). At both 7 and 14 days, Na-K-ATPase activity in the cortex of untreated diabetic rats was also significantly increased compared with nondiabetic control rats and the increase was prevented by myo-inositol or Sorbinil. Myo-inositol or Sorbinil did not reduce Na-K-ATPase activity of nondiabetic control rats, nor did they prevent the increase in medullary Na-K-ATPase in compensatory hypertrophy following uninephrectomy. Myo-inositol content of outer medulla was about five to six times that of cortex, but was unaltered by the diabetic state.(ABSTRACT TRUNCATED AT 250 WORDS)

Effect of meglumine iothalamate on renal hemodynamics and function in the diabetic rat.

Diabetic rats were given an intravenous (external jugular vein) injection of 3 mg/kg of 60% meglumine iothalamate to test for this contrast agent's functional effects on the kidney. Rats were made diabetic by the intravenous injection of 60 mg/kg streptozotocin six months prior to the experiment and received no treatment during the interim. Glomerular filtration rate, renal blood flow, blood pressure, and sodium reabsorption were measured immediately before and at timed intervals after the administration of the contrast agent. In the diabetic rats, meglumine iothalamate caused a small and brief increase in renal blood flow followed by a sustained decrease; in the control animals an initial rapid rise was followed by a sustained elevation. Glomerular filtration rate also decreased slightly after contrast agent injection and remained depressed below baseline in the diabetic rats, whereas in the control animals it rose slightly above baseline and returned to control values by the end of the experiment. Sodium reabsorption was initially much higher than that of the controls, and it remained much higher throughout the experiment but decreased slightly just after injection of the contrast agent. Volume expansion of the diabetic animals decreased fractional sodium reabsorption to levels similar to those of the control rats but did not normalize the response of renal blood flow, glomerular filtration rate, or sodium reabsorption. Dehydration of control animals increased initial sodium reabsorption to levels similar to those of the diabetic animals but did not normalize the response to the contrast agent of the glomerular filtration rate, renal blood flow, or sodium reabsorption.(ABSTRACT TRUNCATED AT 250 WORDS)